AC-11 Supplement and Biological Aging

Investigation of AC-11® Supplementation in Reversing Epigenetic Markers of Biological Aging Including Those Related to Telomere Length

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05310123

Enrollment

Registered

2022-04-04

Start date

2021-05-26

Completion date

2022-10-31

Last updated

2022-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aging

Brief summary

This is a prospective non-randomized clinical study of 24 patients to evaluate the effects of the AC-11®. The study will evaluate the effectiveness of the supplement's ability to reverse epigenetic markers of biological age. The duration of the study will be 6 months.

Interventions

DIETARY_SUPPLEMENTAC-11

6-months of treatment with AC-11

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Intervention model description

prospective, non-randomized

Eligibility

Sex/Gender

ALL

Age

55 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

1. Men and women of any ethnicity. 2. Age Range 55 years and older 3. The patient must be able to comply with the treatment plan and laboratory tests

Exclusion criteria

1. Neoplastic cancer within 5 years prior to screening, except for cutaneous basal cell or squamous cell cancer resolved by excision 2. No immune system issues or immunodeficiency disease 3. No history of viral illness which could be reactivated by immune downregulation 4. Presence of clinically significant acute or unstable cardiovascular and cerebrovascular (stroke) 5. Diagnosis of a transient ischemic attack in the 6 months prior to screening 6. Patients infected with hepatitis C or HIV 7. Patients with Body Mass Index (BMI) \> 40 kg/m2 8. Presence of active infection 9. Any other illness, psychiatric disorder, alcohol or chemical dependence that in the opinion of the investigator would render a patient unsuitable to participate in the study 10. Unable or unwilling to provide a required blood sample for testing 11. As for the male-participants they are recommended to avoid fertilization for the first 6 months after the clinical trial. 12. If the patient has previously used AM/PM HealthSpan system supplements at any time before the start of the trial.

Design outcomes

Primary

Measure	Time frame	Description
Methylation age clock testing	Change in epigenetic age from baseline to 6 months	Epigenetic testing
Telomere Test	Change in telomere length from baseline to 6 months	Epigenetic testing

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026